Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726471PMC
http://dx.doi.org/10.1017/ash.2022.229DOI Listing

Publication Analysis

Top Keywords

dalbavancin administration
8
clinical outcomes
4
outcomes dalbavancin
4
administration patients
4
patients barriers
4
barriers outpatient
4
outpatient parenteral
4
parenteral antimicrobial
4
antimicrobial therapy
4
therapy 2016
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!